Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $2.8 million for the fourth quarter, which includes non-cash charges of about $1 million, reconciling to a non-GAAP loss of $942,000 [32][34] - The equity method investment balance at the end of the year was $34 million, reflecting an $8.5 million year-over-year increase consistent with a 33% increase in Lucid stock during 2025 [25][26] - The cash burn rate for the fourth quarter was $1.5 million, which included approximately $600,000 of outside contractor development costs associated with the implantable device [24] Business Line Data and Key Metrics Changes - Lucid reported fourth quarter 2025 EsoGuard revenue of approximately $1.5 million, with EsoGuard test volume increasing by 29% from the third quarter [9] - Veris is advancing a cancer care platform and has completed full Epic integration with Ohio State University, receiving positive feedback from senior leadership and clinicians [11][12] - The company is relaunching its MedTech portfolio, with a new Chief Business Officer overseeing the medical device subsidiaries [18][19] Market Data and Key Metrics Changes - PAVmed remains the largest shareholder of Lucid Diagnostics, holding approximately 18% of the common shares outstanding, which provides significant influence despite no longer having voting control [26] - The company has received inquiries from various banks and companies seeking partnerships in medical technologies following the completion of its restructuring [20][66] Company Strategy and Development Direction - The company aims to operate as a high-growth, diversified commercial life sciences company with multiple independently financed subsidiaries [5] - A key aspect of the future plan includes relaunching the MedTech portfolio and engaging in new technologies, particularly in the GI space [7][66] - The strategic vision for Veris is evolving from remote patient monitoring to include AI-based clinical decision support tools [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's improved capital structure and ability to execute its strategic plan, highlighting the successful removal of toxic convertible securities [4][5] - The company is focused on achieving key milestones in its subsidiaries, particularly in the context of Lucid's upcoming Medicare coverage and Veris's implantable device development [6][9] - Management emphasized the importance of the commercial relationship with Ohio State University and the structured plan to roll out the Veris platform across various departments [39][42] Other Important Information - The company has engaged a new leader for its medical device portfolio, which includes the licensing of endoscopic imaging technology from Duke University [19][55] - The recent financing has positioned the company with total assets over $100 million and $15 million of long-term debt, enhancing its financial strength [27][29] Q&A Session Summary Question: What are the key metrics for the commercial relationship with OSU? - Management indicated a target of 1,000 patients within the first year and a structured plan to roll out the platform across various departments [38][39] Question: Are the new risk stratification tools part of the contract with OSU? - Management clarified that the development of AI-based tools requires extensive data and discussions with OSU are ongoing regarding their integration [48][51] Question: What is the status of the imaging technology licensed from Duke? - Management stated that the technology is in early phases, with modifications underway for a broader commercial launch [55][59]

Financial Data and Key Metrics Changes - Total operating expenses for 2025 increased compared to the fourth quarter and full year 2024, driven by clinical operations and development expenses, including increased manufacturing and process development costs associated with the ongoing pivotal FORTIFY-HN01 study [20] - The company anticipates an increase in operating expenses for 2026, driven by increased investment in clinical operations and early commercial and medical infrastructure [21] - As of year-end 2025, the company entered 2026 with $414.8 million in cash equivalents and marketable securities, and raised an additional $161.8 million in net proceeds via an oversubscribed public offering [21][22] Business Line Data and Key Metrics Changes - The lead asset, ficerafusp alfa, is a bifunctional EGFR-directed antibody combined with the TGF-beta ligand trap, showing promising clinical data in treating HPV-negative recurrent and metastatic head and neck cancer [5][6] - Clinical experience reported in approximately 90 patients across three phase Ib cohorts demonstrated a median overall survival of 21.3 months, nearly tripling the median overall survival observed with standard care [9][12] Market Data and Key Metrics Changes - The head and neck cancer market is projected to exceed $5 billion in global sales in the 2030s, with HPV-negative patients representing the majority of patients in the front-line recurrent metastatic setting [15][16] - The company aims to significantly expand the market by increasing the number of patients responding to therapy and improving the duration of response compared to standard care [16] Company Strategy and Development Direction - Bicara Therapeutics is focused on advancing ficerafusp alfa towards a pivotal study interim analysis expected in mid-2027, with plans to develop a less frequent dosing regimen [8][18] - The company is preparing for a potential U.S. launch and is investing in commercial and medical infrastructure, including hiring a Chief Commercial Officer [14][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical data supporting ficerafusp alfa's differentiated profile compared to other investigational agents in the head and neck cancer space [14] - The company is optimistic about the momentum in patient enrollment for the FORTIFY-HN01 study, particularly in regions with high smoking prevalence [25][27] Other Important Information - Bicara received breakthrough therapy designation from the FDA for ficerafusp alfa in combination with pembrolizumab for the first-line treatment of patients with metastatic or unresectable HPV-negative recurrent head and neck squamous cell carcinoma [6][7] - The company is exploring the potential for ficerafusp alfa in earlier lines of therapy for head and neck cancer, which could significantly expand the market opportunity [40][41] Q&A Session Summary Question: Can you provide more color on patient demand and willingness to participate in the pivotal FORTIFY study? - Management noted significant momentum in patient enrollment, particularly in U.S. and ex-U.S. sites, with an estimated enrollment of 150-200 patients for the separate study of the less frequent dosing regimen [24][25] Question: What is the scope of the colorectal cancer update expected in the second half of the year? - The company plans to present data on cohorts with no less than 20 patients each, focusing on third-line treatment populations [30][32] Question: Can you quantify substantial enrollment for the FORTIFY study? - Substantial enrollment is defined as meaningful enrollment to ensure no bias is introduced into the confirmatory study, with a focus on achieving full enrollment for the interim analysis [53][54] Question: How does the company view the competitive landscape and market share capture? - Management believes there is significant momentum at all sites, and they do not see competitive overlap as a major concern [45] Question: What is the rationale for the new loading and maintenance strategy? - The company is confident in the proposed strategy based on extensive exposure response modeling across different dosing regimens [60]

Financial Data and Key Metrics Changes - In Q4 2025, consolidated net revenue surged by 131.8% year-over-year to $58.80 million, while for the full year, consolidated net revenue reached $100.19 million, representing an 11% increase over 2024 [4][15] - Gross profit for Q4 2025 was approximately $4.28 million, with a gross margin of 7.3%, down from 13.1% in Q4 2024 [14] - For the full year 2025, gross profit was about $18.42 million, representing a margin of 9.4%, down from 23.7% in 2024 [15][16] Business Line Data and Key Metrics Changes - Battery business revenues in Q4 2025 were about $30.82 million, an increase of 35.8% year-over-year, while LEV revenues skyrocketed by 524.2% to $12.92 million [13][14] - Hitrans segment generated $27.98 million in Q4 2025, a massive 944.1% surge from Q4 2024, reflecting the upward cycle in raw material pricing [14][10] - For the full year, Hitrans contributed $188.92 million, up by 123%, while the battery business contributed $105.98 million [15] Market Data and Key Metrics Changes - Revenue from LEVs increased by 252% year-over-year to $36.36 million for the full year [8] - The company has established collaborations with international blue-chip customers, including Anker Innovations and Scania, enhancing its market presence [8] Company Strategy and Development Direction - The company is undergoing a structural upgrade of its product portfolio and aggressive capacity expansion, focusing on next-generation battery technologies [4][11] - A strategic partnership with Spiro in Africa has been formed, with plans to explore further collaborative models to assist in localized business expansion [7] - The company is localizing its global supply chain to mitigate the impact of export tax rebate reductions in China [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record high consolidated sales in 2026, driven by demand for new battery models and completion of capacity ramp-ups [11][19] - The company anticipates a rebound in gross margins as production ramps up, with expectations for improvement in the second half of 2026 [23][24] Other Important Information - The company is constructing a new manufacturing facility in Malaysia to diversify its supply chain [9] - A redomicile merger to change incorporation from Nevada to the Cayman Islands has been approved to streamline operations [11] Q&A Session Summary Question: What are the expectations for gross margins in the battery business? - Management indicated that gross margins are expected to improve as capacity ramps up, with the Dalian facility expected to complete its ramp-up in the first half of 2026 [22][23] Question: Can you elaborate on the cell packing business and its growth potential? - Management confirmed a substantial order from a major African customer and highlighted the establishment of a battery pack assembly unit dedicated to this market [25][26] Question: Are there any developments in energy storage related to grid storage? - Management stated that current focus is on household and portable energy storage, with ongoing R&D for larger prismatic cells for grid storage applications [31][32]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company ended the year with $182.5 million in cash equivalents and marketable securities, which is expected to support operations into the third quarter of 2027 [20] - The total net loss for 2025 was comparable to the same period in 2024 [20] Business Line Data and Key Metrics Changes - The company reported significant clinical progress in its pipeline, including advancements in NMRA-511, Navacaprant, and NMRA-215, with multiple clinical data readouts expected in 2026 [4][5] - NMRA-511 demonstrated a clinically meaningful effect size in Alzheimer's disease agitation, with a favorable safety profile [6][10] - Navacaprant studies are fully enrolled with over 400 patients in each study, with data expected in the second quarter of 2026 [12] - NMRA-215 showed class-leading weight loss in a 12-week diet-induced obesity study, although unexpected adverse findings were reported in a separate toxicology study [9][19] Market Data and Key Metrics Changes - The company is focusing on advancing programs with best-in-class pharmacology and brain-penetrant chemistry, targeting novel mechanisms of action to deliver transformative therapies [5] - The competitive landscape includes other companies in the CNS space, with NMRA-898 positioned as a lead program in schizophrenia based on promising clinical results [14][59] Company Strategy and Development Direction - The company aims to advance the next generation of novel therapies for brain diseases, with a clear mission to improve treatment outcomes and quality of life for patients [4] - The strategy includes prioritizing obesity as a lead indication for NMRA-215 and advancing NMRA-898 for schizophrenia [8][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the science and the dedication of the team to deliver innovative therapies [5] - The company is well-positioned to achieve multiple potentially value-creating milestones within the next 12 months [5] Other Important Information - The company has opened a for-cause audit regarding the unexpected findings in the NMRA-215 toxicology study and is conducting a repeat study [19][48] - The company is exploring higher doses of NMRA-511 in a MAD extension cohort, with data expected in the second half of 2026 [11] Q&A Session Summary Question: Clarification on Navacaprant filing - Management confirmed that a positive result from either KOASTAL-2 or KOASTAL-3, along with supportive data, would position the company to request a pre-NDA meeting with the FDA [22][23] Question: Conduct issues related to NMRA-215 - Management indicated that the conduct issues were procedure-related and emphasized that repeating the study is a common practice in the industry [26][27] Question: Details on NMRA-898's lead program - Management explained that NMRA-898 was prioritized due to its compelling data, while NMRA-861 remains a viable compound for future indications [30][32] Question: Update on NMRA-215 maintenance data - Management confirmed that the data from the DIO study validated the hypothesis of maintaining weight loss and that the next step is to move the program into the clinic [41][43] Question: Guidance from the FDA on NMRA-215 - Management stated that they have not discussed the studies with the FDA but are confident that the repeat study will allow them to clear the IND [47][48] Question: Effect size changes in NMRA-511 - Management reported consistent effect sizes across different time points and plans to move forward with a MAD cohort for NMRA-511 [51][52]

Financial Data and Key Metrics Changes - In Q4 2025, consolidated net revenue surged by 131.8% year-over-year to $58.80 million, while full-year consolidated net revenue reached $195.19 million, representing an 11% increase over 2024 [4][15]. - Gross profit for Q4 2025 was approximately $4.28 million, resulting in a gross margin of 7.3%, down from 13.1% in Q4 2024 [14]. - Full-year gross profit was about $18.42 million, with a margin of 9.4%, down from 23.7% in 2024 [16]. Business Line Data and Key Metrics Changes - Battery business revenues in Q4 2025 were about $30.82 million, a 35.8% increase year-over-year, despite a 10.6% decrease in the energy storage sector due to the phase-out of the legacy Model 26650 [13][14]. - LEV revenues skyrocketed by 524.2% to $12.92 million in Q4 2025 [14]. - Hitrans segment generated $27.98 million in Q4 2025, a massive 944.1% surge from Q4 2024, benefiting from rising raw material prices [14]. Market Data and Key Metrics Changes - Revenue from LEVs increased by 252% year-over-year to $36.36 million for the full year [8]. - The company has established collaborations with international blue-chip customers, including Anker Innovations and Scania, enhancing its market presence [8]. - The PRC government's phase-out policy for export tax rebates is expected to impact margins, prompting the company to localize its supply chain [9]. Company Strategy and Development Direction - The company is undergoing a structural upgrade of its product portfolio and expanding capacity, particularly with the new Model 40135 cells and Model 32140 cells [4][5]. - A strategic partnership with Spiro in Africa aims to enhance battery swapping infrastructure, with plans for further collaboration [7]. - The company is also focusing on battery pack integration to serve end users directly, bypassing intermediate integrators [6]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record high consolidated sales in 2026, driven by demand for new battery models and capacity ramp-ups [11]. - The company anticipates a rebound in gross margins as production ramps up and customer transitions are completed [23]. - A robust financial foundation is maintained, with cash and cash equivalents increasing to $75.68 million by the end of 2025 [18]. Other Important Information - The company is expanding its raw material segment, Hitrans, which is expected to reach new performance highs due to ongoing upward cycles in raw material prices [10]. - A redomicile merger to change the place of incorporation from Nevada to the Cayman Islands has been approved to streamline operations [11]. Q&A Session Summary Question: What are the expectations for gross margins in the battery business? - Management indicated that gross margins are expected to improve as capacity ramps up, with a target for better margins in the second half of 2026 [22][24]. Question: Can you elaborate on the cell packing business and its growth potential? - The company has received substantial orders from a major African customer and is setting up a battery pack assembly unit to support this growth [25][26]. Question: Is there any impact on energy storage related to grid storage and BESS companies? - Currently, the focus is on smaller ESS products, with ongoing R&D for larger prismatic cells aimed at grid-sized energy storage systems [32].

Financial Data and Key Metrics Changes - The net loss for the year ended December 31, 2025, was approximately $34.5 million or $0.74 per basic and diluted share, compared to a net loss of $37.6 million or $1.03 per basic and diluted share for the year ended December 31, 2024, indicating an improvement in financial performance [15] - Research and development expenses for the year ended December 31, 2025, were $19 million, down from $22.6 million in 2024, primarily due to decreases in manufacturing and personnel costs [15] - General and administrative expenses decreased to $12.5 million in 2025 from $13.8 million in 2024, reflecting a reduction in personnel costs [16] Business Line Data and Key Metrics Changes - The company reported encouraging early results from the PDS-01ADC trial, showing a median progression-free survival (PFS) of 9.6 months and a 40% decline in prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer [5][6] - The VERSATILE-002 trial demonstrated a median overall survival of 39.3 months for patients with HPV-16 positive head and neck cancer, marking a significant clinical achievement [9] Market Data and Key Metrics Changes - The company highlighted the growing unmet need for effective therapies in HPV-16 positive cancers, which are rapidly increasing in the U.S. and EU due to low vaccination rates [12] - The company’s PDS0101 is positioned as the only subcutaneous injection product in late-stage development for recurrent and/or metastatic head and neck squamous cell carcinoma, offering a more convenient treatment option [11] Company Strategy and Development Direction - The company is focused on advancing PDS0101 as a promising treatment option for HPV-16 positive head and neck cancer, with an amended protocol for the VERSATILE-003 trial aimed at accelerating approval timelines [4][10] - The strategic decision to amend the VERSATILE-003 trial to include PFS as a primary endpoint is expected to shorten trial duration and reduce costs while maintaining overall survival as a basis for full approval [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 to provide a well-tolerated treatment option for the growing population of HPV-16 positive patients, emphasizing the lack of effective therapies currently available [14] - The company anticipates meaningful opportunities ahead as it continues to execute its priorities in 2026, supported by early data from the PDS-01ADC program and expanded patient protections [38] Other Important Information - The company has strengthened its intellectual property portfolio with new patents granted in the U.S. and Japan, extending market protection for PDS0101 into the 2040s [6] Q&A Session Summary Question: What will the revised enrollment target look like for the amended protocol? - The trial duration has been shortened to about a year for final results, with PFS being the interim analysis available in approximately a year and a half [20] Question: How should R&D expenses be expected for 2026 with the smaller trial design? - While specific financial guidance was not provided, R&D costs are expected to increase as the trial is reinitiated and patient enrollment begins [23] Question: How will patients already enrolled prior to the VERSATILE-003 pause be handled? - Patients who started on the trial will continue their treatment as indicated by the protocol, and they will be included in a special subset of the data for safety analysis [27] Question: What are the powering assumptions for the interim PFS and the new sample size for the phase III? - The sample size has not been made public yet, but the PFS is powered to detect statistically significant changes, with two analyses planned [34]

Financial Data and Key Metrics Changes - The net loss for the year ended December 31, 2025, was approximately $34.5 million or $0.74 per basic and diluted share, compared to a net loss of $37.6 million or $1.03 per basic and diluted share for the year ended December 31, 2024, indicating an improvement in financial performance [15] - Research and development expenses for the year ended December 31, 2025, were $19 million, down from $22.6 million in 2024, primarily due to decreases in manufacturing and personnel costs [15] - General and administrative expenses decreased to $12.5 million in 2025 from $13.8 million in 2024, reflecting a reduction in personnel costs [16] Business Line Data and Key Metrics Changes - The company reported encouraging early results from the PDS-01ADC trial, showing a median progression-free survival (PFS) of 9.6 months and a 40% median decline in prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer [5][6] - The VERSATILE-002 trial demonstrated a median overall survival of 39.3 months for patients with HPV-16 positive head and neck cancer, marking a significant clinical achievement [9] Market Data and Key Metrics Changes - The company highlighted the growing unmet need for treatments in HPV-16 positive cancers, which are rapidly increasing in the U.S. and EU due to low vaccination rates [12] - The amendment to the VERSATILE-003 trial protocol aims to accelerate the availability of PDS0101 to the growing population of HPV-16 positive patients [11] Company Strategy and Development Direction - The company is focused on advancing PDS0101 as a promising treatment option for HPV-16 positive head and neck cancer, with a strategic amendment to the VERSATILE-003 trial to include PFS as a primary endpoint [4][10] - The company has strengthened its intellectual property portfolio with new patents granted in the U.S. and Japan, extending market protection into the 2040s [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 to provide a well-tolerated treatment option without chemotherapy for HPV-16 positive patients, who currently lack effective therapies [14] - The company anticipates meaningful opportunities ahead as it continues to execute its priorities in 2026, particularly with the early data from the PDS-01ADC program [38] Other Important Information - The company emphasized the convenience of PDS0101 as a subcutaneous injection requiring only five doses, compared to over twenty doses for most therapeutic approaches [12] Q&A Session Summary Question: What will the revised enrollment target look like for the amended protocol? - The trial duration has been shortened to about a year for final results, with the interim analysis for PFS expected in approximately a year and a half [20] Question: How should R&D expenses be expected for 2026 with the smaller trial design? - While specific financial guidance was not provided, R&D costs are expected to increase once the trial is reinitiated, commensurate with site openings and patient enrollment [23] Question: How will patients already enrolled prior to the VERSATILE-003 pause be handled? - Patients who started on the trial will continue their treatment as indicated by the protocol, and they will be included in a special subset of the data for safety [27] Question: What is the expected enrollment pace based on last year's execution? - The enrollment pace is expected to be robust due to positive responses from sites and less competition compared to when the trial first began [29] Question: Can you share the powering assumptions for the interim PFS and the new sample size for the phase III? - The sample size has not been made public yet, but the PFS is powered to detect statistically significant changes, with two interim analyses planned [34]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash equivalents and marketable securities totaling $182.5 million, which is expected to support operations into the third quarter of 2027 [20] - The total net loss for 2025 was comparable to the same period in 2024, indicating stable financial performance despite ongoing investments in clinical programs [20] Business Line Data and Key Metrics Changes - The company made significant clinical progress with NMRA-511, an oral vasopressin 1A receptor antagonist, showing a clinically meaningful effect size in Alzheimer's disease agitation [4][6] - Navacaprant, a kappa-opioid receptor antagonist for major depressive disorder, has fully enrolled over 400 patients in two phase III studies, with data expected in the second quarter of 2026 [12][13] - NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity, demonstrated class-leading weight loss in preclinical studies, although unexpected adverse findings were reported in a toxicology study [9][19] Market Data and Key Metrics Changes - The company is focusing on advancing programs with best-in-class pharmacology and brain-penetrant chemistry, targeting novel mechanisms of action to deliver transformative therapies [5] - The competitive landscape for obesity treatments is evolving, with NMRA-215 showing potential for both monotherapy and combination therapy with existing treatments like semaglutide [17][43] Company Strategy and Development Direction - Neumora's mission is to advance the next generation of novel therapies for brain diseases, with a clear focus on clinical milestones expected within the next 12 months [4][5] - The company is prioritizing NMRA-898 as the lead program in the M4 PAM franchise for schizophrenia, based on promising early clinical results [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of their science and the dedication of their team to deliver innovative therapies for patients with brain diseases [5] - The company is optimistic about achieving multiple value-creating milestones in 2026, particularly with NMRA-511 and navacaprant [5][6] Other Important Information - The company has opened a for-cause audit regarding the unexpected findings in the NMRA-215 toxicology study and is conducting additional studies to ensure safety and efficacy [19][48] - The management team emphasized the importance of maintaining a strong financial foundation while advancing their clinical pipeline [4][20] Q&A Session Summary Question: Clarification on navacaprant filing - Management confirmed that a positive result from either KOASTAL-2 or KOASTAL-3, along with supportive data, would position them well for a pre-NDA meeting with the FDA [22][23] Question: Conduct issues related to NMRA-215 - Management indicated that the conduct issues were likely procedure-related and emphasized that such findings are common in the industry [26][27] Question: Details on NMRA-898's lead program - Management highlighted NMRA-898's compelling data and its potential for once-daily dosing, while NMRA-861 remains a viable option for future indications [30][31] Question: Pre-specified analysis for KOASTAL studies - Management explained that the pre-specified analysis would include top-line data for both studies and insights from the post-pause pooled population [35][37] Question: Maintenance data for NMRA-215 - Management confirmed that the data from the DIO study validated their hypothesis regarding weight loss maintenance and indicated plans for further clinical exploration [41][43] Question: FDA guidance on NMRA-215 - Management stated that they have not yet discussed the studies with the FDA but are confident that the repeat study will allow them to clear the IND [47][48]

Financial Data and Key Metrics Changes - In Q4 2025, consolidated net revenue surged by 131.8% year-over-year to $58.80 million, while full-year consolidated net revenue reached $100.19 million, representing an 11% increase over 2024 [4][14] - The gross profit for Q4 2025 was approximately $4.28 million, resulting in a gross margin of 7.3%, down from 13.1% in Q4 2024 [16] - For the full year 2025, net revenues were $195.19 million, up by about 11% year-over-year, with a gross profit of about $18.42 million, reflecting a margin of 9.4%, down from 23.7% in 2024 [17][18] Business Line Data and Key Metrics Changes - Battery business revenues in Q4 2025 were about $30.82 million, an increase of 35.8% year-over-year, while LEV revenues skyrocketed by 524.2% to $12.92 million [14][15] - The Hitrans segment generated $27.98 million in Q4 2025, a massive 944.1% surge from Q4 2024, driven by rising raw material prices [15][16] - For the full year, Hitrans contributed $188.92 million, up by 123%, while the battery business contributed $105.98 million [17] Market Data and Key Metrics Changes - Revenue from LEVs increased by 252% year-over-year to $36.36 million for the full year, reflecting strong demand in international markets [9] - The company has established collaborations with major international clients, including Anker Innovations and Scania, enhancing its market presence [9][10] - The PRC government's phase-out policy for export tax rebates is prompting the company to localize its global supply chain to mitigate impacts on international margins [10] Company Strategy and Development Direction - The company is undergoing a structural upgrade of its product portfolio and expanding capacity, particularly with the new Model 40135 cells and additional production lines [4][5] - A strategic partnership with Spiro in Africa aims to enhance battery swapping infrastructure, indicating a focus on international market expansion [8] - The company is also advancing its corporate structure by redomiciling from Nevada to the Cayman Islands to streamline operations and support international growth [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving record high consolidated sales in 2026, driven by demand for new battery models and completion of capacity ramp-ups [12][21] - The company anticipates a rebound in gross margins as production ramps up and customer transitions to new models are completed [25][26] - The management highlighted the importance of proactive risk management strategies, including financial hedging, to mitigate global volatility [19][20] Other Important Information - The company is investing in R&D to develop advanced large format cylindrical models and sodium-ion chemistries for extreme conditions [18] - A significant operational turnaround is expected as the company scales its next-generation capacity and expands its global footprint [21] Q&A Session Summary Question: What are the expectations for gross margins in the battery business? - Management indicated that gross margins are expected to improve as capacity ramps up, with a target for better margins in the second half of 2026 [25][26] Question: Can you elaborate on the cell packing business and its growth potential? - Management confirmed substantial orders from a major African customer and emphasized the potential for deeper collaboration, particularly in the LEV market [27][28] Question: Are there any developments in energy storage related to grid storage? - Currently, the focus is on household and portable storage, with ongoing R&D for larger prismatic cells aimed at grid-scale energy storage systems [33][34]

Financial Data and Key Metrics Changes - The net loss for the year ended December 31, 2025, was approximately $34.5 million or $0.74 per share, compared to a net loss of $37.6 million or $1.03 per share for the year ended December 31, 2024, indicating an improvement in financial performance [15] - Research and development expenses decreased to $19 million in 2025 from $22.6 million in 2024, primarily due to reductions in manufacturing and personnel costs [15] - General and administrative expenses also decreased to $12.5 million in 2025 from $13.8 million in 2024, reflecting a reduction in personnel costs [16] Business Line Data and Key Metrics Changes - The company reported encouraging early results from the PDS-01ADC trial, showing a median progression-free survival (PFS) of 9.6 months and a 40% decline in prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer [5][6] - The VERSATILE-002 trial demonstrated a median overall survival of 39.3 months for patients with HPV-16 positive head and neck cancer, marking a significant clinical achievement [9] Market Data and Key Metrics Changes - The company highlighted the growing unmet need for treatments in HPV-16 positive head and neck cancer, which is rapidly increasing in the U.S. and EU due to low vaccination rates [12] - The amendment to the VERSATILE-003 trial protocol aims to accelerate the regulatory submission process, addressing the urgent need for effective therapies in this patient population [11] Company Strategy and Development Direction - The company is focused on advancing PDS0101 as a promising treatment option for HPV-16 positive head and neck cancer, with a strategic amendment to the VERSATILE-003 trial to include PFS as a primary endpoint [4][10] - The company has strengthened its intellectual property portfolio, extending market protection for PDS0101 into the 2040s, which is expected to enhance its competitive position [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 to provide a well-tolerated treatment option without chemotherapy for the growing population of HPV-16 positive patients [14] - The company anticipates meaningful opportunities ahead as it continues to execute its priorities in 2026, with a focus on clinical development and regulatory progress [38] Other Important Information - The company has received new patents in the U.S. and Japan for PDS0101, enhancing its market exclusivity and competitive edge [6] - The cash balance as of December 31, 2025, was reported at $26.7 million, providing a financial cushion for ongoing operations [16] Q&A Session Summary Question: What will the revised enrollment target look like for the amended protocol? - The trial duration has been shortened to about a year for final results, with the interim analysis for PFS expected in approximately a year and a half [20] Question: How should R&D expenses be expected for 2026 with the smaller trial design? - While specific financial guidance was not provided, R&D costs are expected to increase as the trial is reinitiated and sites are opened [23] Question: How will patients already enrolled prior to the VERSATILE-003 pause be handled? - Patients will continue their treatment as indicated by the protocol and will be included in a special subset for safety analysis [27] Question: What is the expected enrollment pace based on last year's execution? - The enrollment pace is expected to be robust due to positive responses from sites and reduced competition in the market [28] Question: Can you share the powering assumptions for the interim PFS and the new sample size for the phase III? - The sample size has not been made public yet, but the PFS analysis is powered to detect statistically significant changes [34]